

Rev04
Update: Oct,19,2022

DATASHEET

Anti-Nivolumab Antibody, pAb, Rabbit

Cat. No.: A01931

Overview

Specificity	The product is specific for Nivolumab. This antibody serves as an excellent positive control for Nivolumab immunogenicity (ADA) assays.
Host Species	Rabbit
Immunogen	Nivolumab
Conjugate	Unconjugated

Applications

Working concentrations for specific applications should be determined by the investigators. The appropriate concentration may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.


Application	Recommended Usage
ELISA	0.02-1 µg/ml

Properties

Form	Lyophilized
Storage Buffer	lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL.
Storage Instructions	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
Purification	Antigen affinity purification
Isotype	Rabbit IgG

Clonality	Polyclonal
Clone ID	Not applicable
Note	GenScript can customize this product per customer's request including product size, buffer components, etc.

Examples



ELISA binding of Anti-Nivolumab Antibody, pAb, Rabbit (GenScript, A01931-40) with Nivolumab.
Coating antigen: Nivolumab, 1 µg/ml.
Anti-Nivolumab Antibody, pAb, Rabbit (GenScript, A01931-40) dilution start from 1,000 ng/ml, EC_{50} = 12.42 ng/ml.

Background

Target Background : Nivolumab (Opdivo) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Nivolumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells.

Synonyms : Rabbit polyclonal to Opdivo

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.